ArticleJournal of endocrinological investigation2026
The role of hepatic steatosis Index, fatty liver Index, and metabolic and hormonal biomarkers in differentiating MASLD in polycystic ovary syndrome.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Revisiting ESR in PCOS: an easily obtainable link to immune and metabolic dysregulation.Journal of ovarian research · 2026Article
- Effects of polycystic ovary syndrome on liver, heart, muscle, and pancreatic-related diseases.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePolycystic ovary syndrome (PCOS) is a common endocrinological disorder closely associated with metabolic dysfunction. Metabolic dysfunction-associated steatotic liver disease (MASLD) is a new comprehensive term encompassing metabolic dysregulation and hepatic steatosis. This study aims to evaluate the diagnostic performance of the hepatic steatosis index (HSI), fatty liver index (FLI), and metabolic parameters in detecting MASLD among PCOS patients. It also aims to explore the prevalence of MASLD across PCOS phenotypes to assess phenotype-specific risks.
methodsA retrospective analysis of 1,192 women aged 18-40 years with PCOS, diagnosed based on the Rotterdam criteria, was conducted. Participants were categorized into two groups: MASLD and non-MASLD. Clinical and metabolic parameters were analyzed, including body mass index (BMI), waist-to-hip ratio, lipid profiles, homeostatic model assessment for insulin resistance (HOMA-IR), and liver enzymes. HSI and FLI scores were calculated, and their diagnostic performance was assessed using ROC analysis. Subgroup analysis evaluated the prevalence of MASLD among PCOS phenotypes (A, B, C, D). Multivariate logistic regression identified independent predictors of MASLD.
resultsMASLD prevalence was 25.8%. HSI (AUC: 0.88) and FLI (AUC: 0.89) demonstrated strong diagnostic performance. MASLD patients had significantly higher BMI, HOMA-IR, and triglyceride levels, and lower high-density lipoprotein levels (p < 0.001). Phenotypes A and B exhibited the highest risk of MASLD, with hyperandrogenism emerging as a key factor (p < 0.004).
conclusionHSI, FLI, and metabolic parameters are practical, non-invasive tools for diagnosing MASLD in PCOS patients. Routine screening using these indices may help clinicians detect and manage MASLD early. To reduce MASLD risk, phenotype-specific treatments targeting obesity, insulin resistance, and hyperandrogenism may be recommended.
Indexed as
Identifiers
41288908What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.